PT UBC Medical Indonesia Tbk (IDX:LABS)

IDX:LABS Statistics

Total Valuation

IDX:LABS has a market cap or net worth of IDR 545.10 billion. The enterprise value is 551.86 billion.

Market Cap	545.10B
Enterprise Value	551.86B

Important Dates

The last earnings date was Friday, June 20, 2025.

Earnings Date	Jun 20, 2025
Ex-Dividend Date	n/a

Share Statistics

IDX:LABS has 3.95 billion shares outstanding.

Current Share Class	3.95B
Shares Outstanding	3.95B
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	9.87%
Owned by Institutions (%)	n/a
Float	700.00M

Valuation Ratios

The trailing PE ratio is 140.75.

PE Ratio	140.75
Forward PE	n/a
PS Ratio	3.58
PB Ratio	3.88
P/TBV Ratio	4.02
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 24.20, with an EV/FCF ratio of -20.88.

EV / Earnings	142.50
EV / Sales	3.62
EV / EBITDA	24.20
EV / EBIT	52.02
EV / FCF	-20.88

Financial Position

The company has a current ratio of 2.90, with a Debt / Equity ratio of 0.25.

Current Ratio	2.90
Quick Ratio	1.01
Debt / Equity	0.25
Debt / EBITDA	1.57
Debt / FCF	-1.36
Interest Coverage	3.81

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	6.94%
Revenue Per Employee	2.46B
Profits Per Employee	62.47M
Employee Count	62
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, IDX:LABS has paid 2.34 billion in taxes.

Income Tax	2.34B
Effective Tax Rate	37.64%

Stock Price Statistics

The stock price has decreased by -29.08% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-29.08%
50-Day Moving Average	131.66
200-Day Moving Average	130.52
Relative Strength Index (RSI)	50.67
Average Volume (20 Days)	1,270,240

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, IDX:LABS had revenue of IDR 152.36 billion and earned 3.87 billion in profits. Earnings per share was 0.98.

Revenue	152.36B
Gross Profit	57.70B
Operating Income	10.61B
Pretax Income	6.21B
Net Income	3.87B
EBITDA	22.39B
EBIT	10.61B
Earnings Per Share (EPS)	0.98

Balance Sheet

The company has 29.07 billion in cash and 35.84 billion in debt, giving a net cash position of -6.76 billion or -1.71 per share.

Cash & Cash Equivalents	29.07B
Total Debt	35.84B
Net Cash	-6.76B
Net Cash Per Share	-1.71
Equity (Book Value)	140.60B
Book Value Per Share	35.60
Working Capital	112.20B

Cash Flow

In the last 12 months, operating cash flow was -20.66 billion and capital expenditures -5.76 billion, giving a free cash flow of -26.43 billion.

Operating Cash Flow	-20.66B
Capital Expenditures	-5.76B
Free Cash Flow	-26.43B
FCF Per Share	-6.69

Margins

Gross margin is 37.87%, with operating and profit margins of 6.96% and 2.54%.

Gross Margin	37.87%
Operating Margin	6.96%
Pretax Margin	4.08%
Profit Margin	2.54%
EBITDA Margin	14.69%
EBIT Margin	6.96%
FCF Margin	n/a

Dividends & Yields

IDX:LABS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	0.71%
FCF Yield	-4.85%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

IDX:LABS has an Altman Z-Score of 6.05 and a Piotroski F-Score of 2.

Altman Z-Score	6.05
Piotroski F-Score	2